AORT - Data-Driven Growth Fuels More Upside For Overlooked Artivion

2024-06-21 17:01:54 ET

Summary

• Artivion, Inc. has continued to log double-digit revenue growth with contributions from diverse assets including its stent grafts, heart valves, and cryopreserved tissue grafts.
• Positive post-approval trial data for the On-X aortic valve and a successful PERSEVERE IDE study for AMDS hybrid prosthesis can drive additional revenue growth.
• A strong pipeline, including NEXUS and ARCEVO stent graft systems, can support a longer runway of continued revenue growth.
• A 4x revenue multiple drives a fair value above $30 and still offers room for further re-rating.

I'm not exactly surprised that a sub-$1B growth med-tech continues to be overlooked in the market, but Artivion, Inc. ( AORT ) management is doing the right things to continue developing a growth story fueled by data-backed innovative products in cardiac care....

For further details see: